Sanofi’s appeal fails ; Generic Oxaliplatin to stay in Korea!!

The Patent Court of Korea upheld on June 4 its earlier ruling in favor of Boryung, saying the South Korean company's generic drug for colorectal cancer didn't infringe on a Sanofi patent related to the cancer drug, Boryung officials said.
It's a victory for Boryung against a "multinational pharmaceutical company trying to block access by a local company with a deceptive patent," an official at Boryung said.
Last October, Boryung introduced the generic drug called Oxaliplatin liquid medicine for the first time in the world after winning the lawsuit in July that year. Sanofi filed an appeal in October.
Generic drugs usually sell for lower prices than brand-name medicines as they can be made after patent protection of the original brand expires.
Multinational drugmakers such as Sanofi have allegedly been accused of trying to ban sales of generic drugs by winning new patents for their branded medicines.
Officials at Sanofi's Korean office weren't immediately available for comment.